Cargando…

Donepezil Combined with Natural Hirudin Improves the Clinical Symptoms of Patients with Mild-to-Moderate Alzheimer's Disease: A 20-Week Open-Label Pilot Study

Aim:To evaluate the efficacy and safety of donepezil plus natural hirudin in patients with mild-to-moderate Alzheimer's Disease. Methods: In the 20-week, randomized, open-label and controlled study, 84 patients received either donepezil (5 mg/day for the first 4 weeks and 10 mg/day thereafter)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, De-qiang, Zhou, Yu-ping, Yang, Han
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2012
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3354329/ https://www.ncbi.nlm.nih.gov/pubmed/22606044 http://dx.doi.org/10.7150/ijms.4363

Ejemplares similares

Broader Considerations of Higher Doses of Donepezil in the Treatment of Mild, Moderate, and Severe Alzheimer's Disease
por: Berk, Camryn, et al.
Publicado: (2012)

Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer's Dementia after Failure to Respond to Donepezil
por: Hwang, Tae-Young, et al.
Publicado: (2016)

Modulation of Brain Activity and Functional Connectivity by Acupuncture Combined With Donepezil on Mild-to-Moderate Alzheimer's Disease: A Neuroimaging Pilot Study
por: Zhan, Yijun, et al.
Publicado: (2022)

Safety and efficacy of donepezil hydrochloride in patients with mild to moderate Alzheimer's disease: Findings of an observational study
por: Mehta, Suyog, et al.
Publicado: (2012)

The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial
por: Rockwood, Kenneth, et al.
Publicado: (2007)

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease
por: Farlow, Martin, et al.
Publicado: (2011)

The hirudin-like factors HLF3 and HLF4—hidden hirudins of European medicinal leeches
por: Müller, Christian, et al.
Publicado: (2020)

Intepirdine as adjunctive therapy to donepezil for mild‐to‐moderate Alzheimer's disease: A randomized, placebo‐controlled, phase 3 clinical trial (MINDSET)
por: Lang, Frederick M., et al.
Publicado: (2021)

A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil
por: Fullerton, Terence, et al.
Publicado: (2018)

Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial)
por: Knapp, Martin, et al.
Publicado: (2016)

Donepezil for mild cognitive impairment in Parkinson’s disease
por: Baik, Kyoungwon, et al.
Publicado: (2021)

Donepezil Enhances Frontal Functional Connectivity in Alzheimer's Disease: A Pilot Study
por: Griffanti, Ludovica, et al.
Publicado: (2016)

Transdermal donepezil on the treatment of Alzheimer’s disease
por: Sozio, Piera, et al.
Publicado: (2012)

The efficacy of mirtazapine in agitated patients with Alzheimer’s disease: A 12-week open-label pilot study
por: Cakir, Sibel, et al.
Publicado: (2008)

Sodium selenate as a disease-modifying treatment for mild–moderate Alzheimer’s disease: an open-label extension study
por: Vivash, Lucy, et al.
Publicado: (2021)

Hirudin as an anticoagulant for both haematology and chemistry tests
por: Kumura, Takeo, et al.
Publicado: (2000)

Self-regulated hirudin delivery for anticoagulant therapy
por: Xu, Xiao, et al.
Publicado: (2020)

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT
por: Jones, Rob, et al.
Publicado: (2009)

Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease
por: Ferris, Steven H, et al.
Publicado: (2011)

Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer's Disease: A Review of Clinical Trials
por: Molino, Ivana, et al.
Publicado: (2013)

Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease
por: Tariot, Pierre, et al.
Publicado: (2012)

Medihoney Derma Cream Treatment for Mild to Moderate Atopic Dermatitis in Children: An Open-Label Randomized Pilot Study
por: Horev, Amir, et al.
Publicado: (2022)

Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases
por: Pooladgar, Parham, et al.
Publicado: (2022)

Impact of Plasma Donepezil Concentration on Behavioral and Psychological Symptoms of Dementia in Patients with Alzheimer's Disease
por: Kagawa, Yoshiyuki, et al.
Publicado: (2021)

Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer’s disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial
por: Hong, Yun Jeong, et al.
Publicado: (2019)

A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease
por: Deardorff, William James, et al.
Publicado: (2016)

Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region
por: Sabbagh, Marwan, et al.
Publicado: (2016)

Prediction of Treatment Response to Donepezil using Automated Hippocampal Subfields Volumes Segmentation in Patients with Mild Alzheimer's Disease
por: Um, Yoo Hyun, et al.
Publicado: (2017)

Differential response to donepezil in MRI subtypes of mild cognitive impairment
por: Diaz-Galvan, Patricia, et al.
Publicado: (2023)

Effect of acupuncture with donepezil based on syndrome differentiation on cognitive function in patients with mild-to-moderate Alzheimer’s disease: a study protocol for a multicenter randomized controlled trial
por: Fu, Qin-Hui, et al.
Publicado: (2022)

CYP2D6 Predicts Plasma Donepezil Concentrations in a Cohort of Thai Patients with Mild to Moderate Dementia
por: Chamnanphon, Monpat, et al.
Publicado: (2020)

A Multicentre, Randomised, Open-Label, Prospective Study to Estimate the Add-On Effects Of Memantine as Ebixa(®) Oral Pump (Solution) on Language in Patients with Moderate to Severe Alzheimer’s Disease Already Receiving Donepezil (ROMEO-AD)
por: Kim, Hee-Jin, et al.
Publicado: (2023)

Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology
por: Sabbagh, Marwan, et al.
Publicado: (2011)

Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics
por: Cacabelos, Ramón
Publicado: (2007)

Donepezil enhances understanding of degraded speech in Alzheimer's disease
por: Hardy, Chris J. D., et al.
Publicado: (2017)

Donepezil Treatment for Alzheimer's Disease in Chronic Dialysis Patients
por: Yiannopoulou, Konstantina G., et al.
Publicado: (2019)

An Open-Label Exploratory Study with Memantine: Correlation between Proton Magnetic Resonance Spectroscopy and Cognition in Patients with Mild to Moderate Alzheimer's Disease
por: Gordon, Marc L., et al.
Publicado: (2012)

Good rate of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease after three months of treatment: An open-label study
por: de Miranda, Luis Felipe José Ravic, et al.
Publicado: (2013)

The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer’s Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study
por: Yatawara, Chathuri, et al.
Publicado: (2021)

The effect of recombinant hirudin on rabbit ear flaps with venous insufficiency
por: Duzgun, Serdar, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_hd8tiqpnoa40kjfqk0uvkrm3qp